Zelluna (OSE: ZLNA), a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announced a collaboration ...

2022—Cellecta, Inc. today announced the launch of the DriverMap™ Adaptive Immune Receptor (AIR) TCR and BCR kits, a family of multiplex-PCR, NGS-based assays that enable profiling of up to all seven T ...

According to new research, T cells have a nuclear receptor doing something very odd—but very important—to help them fight pathogens and destroy cancer cells. This receptor, called retinoic acid ...

T cells are a critical part of the adaptive immune system that respond to pathogens, tumors, or play a key role in autoimmune diseases. A T cell recognizes potential targets through its T cell ...

Initial clinical data are anticipated from mid-2026.

Among patients with mycosis fungoides (MF) and Sézary syndrome (SS), the T-cell receptor (TCR) clonal Vb20 segment was significantly associated with advanced-stage disease, folliculotropism with ...

Secondary primary malignancies (SPMs) with CAR-T cell therapy in RR-DLBCL from real-world data. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a ...